GENETIC TECHNOLOGIES LIMITED — Director's Dealing 2020

Dec 23, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nicholas Burrows
Date of last notice	3 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	21 December 2020
No. of securities held prior to change	1,670,000 Ordinary shares
Class	Class A Performance Rights
Number acquired	5,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 12 approved by shareholders at the Company’s 10December 2020AnnualGeneral Meeting.
No. of securities held after change	1,670,000 Ordinary shares 5,000,000 Performance Rights

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue Performance Rights issued pursuant to of securities under dividend reinvestment plan, participation in buyresolution 12 approved by shareholders at back the Company’s 10 December 2020 Annual General Meeting.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jerzy Muchnicki
Date of last notice	3 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	MJGD Nominees Pty Ltd
Date of change	21 December 2020
No. of securities held prior to change	MJGD Nominees Pty Ltd 210,436,756 ordinary shares 38,400,000 Ordinary shares (represented by 64,000 American Depositary Receipts) JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares 125,000,000 Unlisted Options MJGD Nominees Pty Ltd (BSMI A/C) 4,849,129 ordinary shares 6,250,000PerformanceRights
Class	7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	57,500,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 13 approved by shareholders at the Company’s 10 December 2020 Annual General Meeting.
No. of securities held after change	MJGD Nominees Pty Ltd 210,436,756 ordinary shares 38,400,000 Ordinary shares (represented by 64,000 American Depositary Receipts) JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares 125,000,000 Unlisted Options MJGD Nominees Pty Ltd (BSMI A/C) 4,849,129 ordinary shares 63,750,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	PerformanceRights issued pursuant to resolution 13 approved by shareholders at the Company’s 10 December 2020 Annual General Meeting.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	3 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd
Date of change	21 December 2020

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	Irwin Biotech Nominees P/L **A/C> 6,200,000 ordinary shares Irwin Biotech Nominees Pty Ltd **A/C> 80,849,310 ordinary shares 5,000,000 Performance Rights Irwin Biotech Nominees Pty Ltd 2,000,000 ordinary shares Irwin Biotech Nominees Pty Ltd 86,582,700 ordinary shares (represented by 144,305 American Depositary Receipts) RIP Opportunities Pty Ltd 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts) RIP Opportunities Pty Ltd **Fund A/C> 124,999,999 ordinary shares 125,000,000 Unlisted Options
Class	7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights
Number acquired	57,500,000Performance Rights
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 14 approved by shareholders at the Company’s 10 December 2020 Annual General Meeting.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change

Irwin Biotech Nominees P/L **A/C> 6,200,000 ordinary shares Irwin Biotech Nominees Pty Ltd **A/C> 80,849,310 ordinary shares 62,500,000 Performance Rights Irwin Biotech Nominees Pty Ltd 2,000,000 ordinary shares Irwin Biotech Nominees Pty Ltd 86,582,700 ordinary shares (represented by 144,305 American Depositary Receipts) RIP Opportunities Pty Ltd 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts) RIP Opportunities Pty Ltd **Fund A/C> 124,999,999 ordinary shares 125,000,000 Unlisted Options

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back

Performance Rights issued pursuant to resolution 14 approved by shareholders at the Company’s 10 December 2020 Annual General Meeting.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lindsay Peter Wakefield
Date of last notice	4 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Wakko Enterprises Pty Ltd
Date of change	21 December 2020
No. of securities held prior to change	Indirect – Wakko Investments Pty Ltd: 3,750,000 Performance Rights Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
Class	Class A Performance Rights
Number acquired	5,000,000
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 15 approved by shareholders at the Company’s 10December 2020AnnualGeneral Meeting.
No. of securities held after change	Indirect – Wakko Investments Pty Ltd: 8,750,000 Performance Rights Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	PerformanceRights issued pursuant to resolution 15 approved by shareholders at the Company’s 10 December 2020 Annual General Meeting.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3